scholarly journals Empirical evidence of cognitive change: Calculating reliable change indices for digital tests of cognition in individuals living with Alzheimer’s disease

2021 ◽  
Vol 17 (S6) ◽  
Author(s):  
John E Harrison ◽  
Jennifer Rae Myers ◽  
Erica N. Madero ◽  
Rachel Mak‐McCully ◽  
Michelle Gray ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Empirical Evidence ◽  
Cognitive Change ◽  
Reliable Change

scholarly journals Detection of Alzheimer’s Disease-Related Cognitive Change With the Mobile Cognitive App Performance Platform

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 801-801
Author(s):  
Dawn Mechanic-Hamilton ◽  
Sean Lydon ◽  
Alexander Miller ◽  
Kimberly Halberstadter ◽  
Jacqueline Lane ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Memory Load ◽  
Memory Task ◽  
Structural Mri ◽  
Cognitive Change ◽  
Difficulty Level ◽  
Trial Duration ◽  
Parahippocampal Cortex ◽  
Relationship Of

Abstract This study investigates the psychometric properties of the mobile cognitive app performance platform (mCAPP), designed to detect memory changes associated with preclinical Alzheimer’s Disease (AD). The mCAPP memory task includes learning and matching hidden card pairs and incorporates increasing memory load, pattern separation features, and spatial memory. Participants included 30 older adults with normal cognition. They completed the mCAPP, paper and pencil neuropsychological tests and a subset completed a high-resolution structural MRI. The majority of participants found the difficulty level of the mCAPP game to be “just right”. Accuracy on the mCAPP correlated with performance on memory and executive measures, while speed of performance on the mCAPP correlated with performance on attention and executive function measures. Longer trial duration correlated with measures of the parahippocampal cortex. The relationship of mCAPP variables with molecular biomarkers, at-home and burst testing, and development of additional cognitive measures will also be discussed.

The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease

2020 ◽  
Vol 78 (2) ◽  
pp. 573-585
Author(s):  
Hyemin Jang ◽  
Hee Jin Kim ◽  
Yeong Sim Choe ◽  
Soo-Jong Kim ◽  
Seongbeom Park ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Interaction Effect ◽  
Significant Interaction ◽  
Amyloid Β ◽  
Cognitive Change ◽  
Significant Interaction Effect ◽  
The Impact

Background: As Alzheimer’s disease (AD) and cerebral small vessel disease (CSVD) commonly coexist, the interaction between two has been of the considerable interest. Objective: We determined whether the association of Aβ and tau with cognitive decline differs by the presence of significant CSVD. Methods: We included 60 subcortical vascular cognitive impairment (SVCI) from Samsung Medical Center and 82 Alzheimer’s disease-related cognitive impairment (ADCI) from ADNI, who underwent Aβ (florbetaben or florbetapir) and tau (flortaucipir, FTP) PET imaging. They were retrospectively assessed for 5.0±3.9 and 5.6±1.9 years with Clinical Dementia Rating-sum of boxes (CDR-SB)/Mini-Mental State Examination (MMSE). Mixed effects models were used to investigate the interaction between Aβ/tau and group on CDR-SB/MMSE changes. Results: The frequency of Aβ positivity (45% versus 54.9%, p = 0.556) and mean global FTP SUVR (1.17±0.21 versus 1.16±0.17, p = 0.702) were not different between the two groups. We found a significant interaction effect of Aβ positivity and SVCI group on CDR-SB increase/MMSE decrease (p = 0.013/p < 0.001), and a significant interaction effect of global FTP uptake and SVCI group on CDR-SB increase/MMSE decrease (p < 0.001 and p = 0.030). Finally, the interaction effects of regional tau and group were prominent in the Braak III/IV (p = 0.001) and V/VI (p = 0.003) not in Braak I/II region (p = 0.398). Conclusion: The association between Aβ/tau and cognitive decline is stronger in SVCI than in ADCI. Therefore, our findings suggested that Aβ positivity or tau burden (particularly in the Braak III/IV or V/VI regions) and CSVD might synergistically affect cognitive decline.

scholarly journals Validation of connected speech as a marker for cognitive change in late‐middle aged African American adults at risk for Alzheimer's disease

2020 ◽  
Vol 16 (S6) ◽  
Author(s):  
Kimberly D. Mueller ◽  
Elizabeth M. Evans ◽  
Sheryl L. Coley ◽  
Rebecca L. Koscik ◽  
Nia Norris ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
African American ◽  
Cognitive Change ◽  
Middle Aged ◽  
Connected Speech ◽  
African American Adults

scholarly journals Tracking Cognitive Change over 24 Weeks with Longitudinal Functional Magnetic Resonance Imaging in Alzheimer’s Disease

2012 ◽  
Vol 9 (4) ◽  
pp. 176-186 ◽  
Author(s):  
Donald G. McLaren ◽  
Aishwarya Sreenivasan ◽  
Eli L. Diamond ◽  
Meghan B. Mitchell ◽  
Koene R.A. Van Dijk ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Magnetic Resonance ◽  
Functional Magnetic Resonance Imaging ◽  
Cognitive Change ◽  
Functional Magnetic Resonance ◽  
Resonance Imaging

Evidence of the Sensitivity of the MoCA Alternate Forms in Monitoring Cognitive Change in Early Alzheimer's Disease

2014 ◽  
Vol 37 (1-2) ◽  
pp. 95-103 ◽  
Author(s):  
Ana Sofia Costa ◽  
Arno Reich ◽  
Bruno Fimm ◽  
Simon Thomas Ketteler ◽  
Joerg Bernhard Schulz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Change ◽  
Alternate Forms ◽  
Early Alzheimer’S Disease

O1-04-02: Beta-amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease

2013 ◽  
Vol 9 ◽  
pp. P132-P132 ◽  
Author(s):  
Yen Ying Lim ◽  
Robb Pietrzak ◽  
Kathryn Ellis ◽  
David Darby ◽  
David Ames ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Beta Amyloid ◽  
Cognitive Change

scholarly journals Genetic Effects on Longitudinal Cognitive Decline During the Early Stages of Alzheimer's Disease

2021 ◽  
Author(s):  
Atul Kumar ◽  
Maryam Shoai ◽  
Sebastian Palmqvist ◽  
Erik Stomrud ◽  
John Hardy ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Genome Wide Association Study ◽  
Early Stage ◽  
Cognitive Change ◽  
Preclinical Ad ◽  
Genome Wide ◽  
A Genome ◽  
Polygenic Scores

Abstract Background Cognitive decline in early-stage Alzheimer’s disease (AD) may depend on genetic variability. Methods In the Swedish BioFINDER study, we used polygenic scores (PGS) (for AD, intelligence and educational attainment), and genetic variants (in a genome-wide association study [GWAS]) to predict longitudinal cognitive change (measured by MMSE) over a mean of 4.2 years. We included 555 β-amyloid (Aβ) negative cognitively unimpaired (CU) individuals, 206 Aβ-positive CU (preclinical AD), 110 Aβ-negative mild cognitive impairment (MCI) patients, and 146 Aβ-positive MCI patients (prodromal AD). Results Polygenic scores for AD (in Aβ-positive individuals) and intelligence (independent of Aβ-status) were associated with cognitive decline. Eight genes were associated with cognitive decline in GWAS (3 independent of Aβ-status). Conclusions AD risk genes may influence cognitive decline in early AD, while genes related to intelligence may modulate cognitive decline irrespective of disease. Therapies targeting the implicated biological pathways may modulate the clinical course of AD.

scholarly journals Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study

Antioxidants ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1839
Author(s):  
Chieh-Hsin Lin ◽  
Hsien-Yuan Lane
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Prospective Study ◽  
Cognitive Decline ◽  
Cognitive Change ◽  
Disease Assessment ◽  
Healthy Individuals

Glutathione (GSH) is a major endogenous antioxidant. Several studies have shown GSH redox imbalance and altered GSH levels in Alzheimer’s disease (AD) patients. Early detection is crucial for the outcome of AD. However, whether GSH can serve as a biomarker during the very early-phase of AD, such as mild cognitive impairment (MCI), remains unknown. The current prospective study aimed to examine the longitudinal change in plasma GSH concentration and its influence on cognitive decline in MCI. Overall, 49 patients with MCI and 16 healthy individuals were recruited. Plasma GSH levels and cognitive function, measured by the Mini-Mental Status Examination (MMSE) and Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog), were monitored every 6 months. We employed multiple regressions to examine the role of GSH level in cognitive decline in the 2 years period. The MCI patients showed significant decline in plasma GSH levels and cognitive function from baseline to endpoint (month 24). In comparison, the healthy individuals’ GSH concentration and cognitive function did not change significantly. Further, both GSH level at baseline and GSH level change from baseline to endpoint significantly influenced cognitive decline among the MCI patients. To our knowledge, this is the first study to demonstrate that both plasma GSH levels and cognitive function declined 2 years later among the MCI patients in a prospective manner. If replicated by future studies, blood GSH concentration may be regarded as a biomarker for monitoring cognitive change in MCI.

Sign in / Sign up

Export Citation Format

Share Document